Parental Broader Autism Subphenotypes in ASD Affected Families: Relationship to Gender, Child's Symptoms, SSRI Treatment, and Platelet Serotonin / Tal LEVIN-DECANINI in Autism Research, 6-6 (December 2013)  

Public ISBD [article]  inAutism Research > 6-6 (December 2013) . - p.621-630 Titre : Parental Broader Autism Subphenotypes in ASD Affected Families: Relationship to Gender, Child's Symptoms, SSRI Treatment, and Platelet Serotonin Type de document : Texte imprimé et/ou numérique Auteurs : Tal LEVIN-DECANINI, Auteur ; Nell MALTMAN, Auteur ; Sunday M. FRANCIS, Auteur ; Steve GUTER, Auteur ; George M. ANDERSON, Auteur ; Edwin H. Jr COOK, Auteur ; Suma JACOB, Auteur Année de publication : 2013 Article en page(s) : p.621-630 Langues : Anglais (eng) Mots-clés : broader autism phenotype  serotonin  autism  SSRI Index. décimale : PER Périodiques Résumé : Relationships between parental broader autism phenotype (BAP) scores, gender, selective serotonin reuptake inhibitor (SSRI) treatment, serotonin (5HT) levels, and the child's symptoms were investigated in a family study of autism spectrum disorder (ASD). The Broader Autism Phenotype Questionnaire (BAPQ) was used to measure the BAP of 275 parents. Fathers not taking SSRIs (F-SSRI; n?=?115) scored significantly higher on BAP Total and Aloof subscales compared to mothers not receiving treatment (M-SSRI; n?=?136.) However, mothers taking SSRIs (M?+?SSRI; n?=?19) scored higher than those not taking medication on BAP Total and Rigid subscales, and they were more likely to be BAPQ Total, Aloof, and Rigid positive. Significant correlations were noted between proband autism symptoms and parental BAPQ scores such that Total, Aloof, and Rigid subscale scores of F-SSRI correlated with proband restricted repetitive behavior (RRB) measures on the ADOS, CRI, and RBS-R. However, only the Aloof subscale score of M?+?SSRI correlated with proband RRB on the ADOS. The correlation between the BAPQ scores of mothers taking SSRIs and child scores, as well as the increase in BAPQ scores of this group of mothers, requires careful interpretation and further study because correlations would not withstand multiple corrections. As expected by previous research, significant parent–child correlations were observed for 5HT levels. However, 5HT levels were not correlated with behavioral measures. Study results suggest that the expression of the BAP varies not only across parental gender, but also across individuals using psychotropic medication and those who do not. En ligne : http://dx.doi.org/10.1002/aur.1322 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=221 [article] Parental Broader Autism Subphenotypes in ASD Affected Families: Relationship to Gender, Child's Symptoms, SSRI Treatment, and Platelet Serotonin [Texte imprimé et/ou numérique] / Tal LEVIN-DECANINI, Auteur ; Nell MALTMAN, Auteur ; Sunday M. FRANCIS, Auteur ; Steve GUTER, Auteur ; George M. ANDERSON, Auteur ; Edwin H. Jr COOK, Auteur ; Suma JACOB, Auteur . - 2013 . - p.621-630. Langues : Anglais (eng) in Autism Research > 6-6 (December 2013) . - p.621-630 Mots-clés : broader autism phenotype  serotonin  autism  SSRI Index. décimale : PER Périodiques Résumé : Relationships between parental broader autism phenotype (BAP) scores, gender, selective serotonin reuptake inhibitor (SSRI) treatment, serotonin (5HT) levels, and the child's symptoms were investigated in a family study of autism spectrum disorder (ASD). The Broader Autism Phenotype Questionnaire (BAPQ) was used to measure the BAP of 275 parents. Fathers not taking SSRIs (F-SSRI; n?=?115) scored significantly higher on BAP Total and Aloof subscales compared to mothers not receiving treatment (M-SSRI; n?=?136.) However, mothers taking SSRIs (M?+?SSRI; n?=?19) scored higher than those not taking medication on BAP Total and Rigid subscales, and they were more likely to be BAPQ Total, Aloof, and Rigid positive. Significant correlations were noted between proband autism symptoms and parental BAPQ scores such that Total, Aloof, and Rigid subscale scores of F-SSRI correlated with proband restricted repetitive behavior (RRB) measures on the ADOS, CRI, and RBS-R. However, only the Aloof subscale score of M?+?SSRI correlated with proband RRB on the ADOS. The correlation between the BAPQ scores of mothers taking SSRIs and child scores, as well as the increase in BAPQ scores of this group of mothers, requires careful interpretation and further study because correlations would not withstand multiple corrections. As expected by previous research, significant parent–child correlations were observed for 5HT levels. However, 5HT levels were not correlated with behavioral measures. Study results suggest that the expression of the BAP varies not only across parental gender, but also across individuals using psychotropic medication and those who do not. En ligne : http://dx.doi.org/10.1002/aur.1322 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=221

A pharmacogenetic study of escitalopram in autism spectrum disorders / Thomas OWLEY in Autism Research, 3-1 (February 2010)  

Public ISBD [article]  inAutism Research > 3-1 (February 2010) . - p.1-7 Titre : A pharmacogenetic study of escitalopram in autism spectrum disorders Type de document : Texte imprimé et/ou numérique Auteurs : Thomas OWLEY, Auteur ; Edwin H. Jr COOK, Auteur ; Bennett L. LEVENTHAL, Auteur ; Camille W. BRUNE, Auteur ; Jeff SALT, Auteur ; Laura WALTON, Auteur ; Steve GUTER, Auteur ; Nelson AYUYAO, Auteur ; Robert D. GIBBONS, Auteur Année de publication : 2010 Article en page(s) : p.1-7 Langues : Anglais (eng) Mots-clés : autistic-disorder escitalopram pharmacogenetics open-label drug-treatment Index. décimale : PER Périodiques Résumé : Objective: To determine the effect of serotonin transporter polymorphism promoter region (5-HTTPLR) genotypic variation (low, intermediate, and high expression groups) on response to escitalopram treatment of children and adolescents with autism spectrum disorders (ASDs). Method: The study used a forced titration, open label design, with genotype blind until study completion. Participants were children and adolescents aged 4-17 years of age with a confirmed ASD (autistic disorder, Asperger's disorder, or pervasive developmental disorder, not otherwise specified). Results: There was an interaction between genotype group and time on the Aberrant Behavior Checklist (ABC) Irritability Subscale (primary outcome variable) (linear maximum marginal likelihood estimation=-4.84, Z=-2.89, SE=1.67, P=0.004). Examination of baseline to last visit revealed that a genotype grouping based on a previous study of platelet 5-HT uptake revealed less response in the genotype group that had S/S genotype for 5-HTTLPR and did not have a diplotype in intron 1 previously shown to be associated with increased platelet 5-HT uptake. Conclusion: This genotype-blind, prospective pharmacogenetic study found the group of subjects with associated with the lowest platelet 5-HT uptake from previous study had the smallest reduction in ABC-Irritability scores after open label treatment with escitalopram. Replication is necessary to confirm these findings. En ligne : http://dx.doi.org/10.1002/aur.109 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=993 [article] A pharmacogenetic study of escitalopram in autism spectrum disorders [Texte imprimé et/ou numérique] / Thomas OWLEY, Auteur ; Edwin H. Jr COOK, Auteur ; Bennett L. LEVENTHAL, Auteur ; Camille W. BRUNE, Auteur ; Jeff SALT, Auteur ; Laura WALTON, Auteur ; Steve GUTER, Auteur ; Nelson AYUYAO, Auteur ; Robert D. GIBBONS, Auteur . - 2010 . - p.1-7. Langues : Anglais (eng) in Autism Research > 3-1 (February 2010) . - p.1-7 Mots-clés : autistic-disorder escitalopram pharmacogenetics open-label drug-treatment Index. décimale : PER Périodiques Résumé : Objective: To determine the effect of serotonin transporter polymorphism promoter region (5-HTTPLR) genotypic variation (low, intermediate, and high expression groups) on response to escitalopram treatment of children and adolescents with autism spectrum disorders (ASDs). Method: The study used a forced titration, open label design, with genotype blind until study completion. Participants were children and adolescents aged 4-17 years of age with a confirmed ASD (autistic disorder, Asperger's disorder, or pervasive developmental disorder, not otherwise specified). Results: There was an interaction between genotype group and time on the Aberrant Behavior Checklist (ABC) Irritability Subscale (primary outcome variable) (linear maximum marginal likelihood estimation=-4.84, Z=-2.89, SE=1.67, P=0.004). Examination of baseline to last visit revealed that a genotype grouping based on a previous study of platelet 5-HT uptake revealed less response in the genotype group that had S/S genotype for 5-HTTLPR and did not have a diplotype in intron 1 previously shown to be associated with increased platelet 5-HT uptake. Conclusion: This genotype-blind, prospective pharmacogenetic study found the group of subjects with associated with the lowest platelet 5-HT uptake from previous study had the smallest reduction in ABC-Irritability scores after open label treatment with escitalopram. Replication is necessary to confirm these findings. En ligne : http://dx.doi.org/10.1002/aur.109 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=993

---

1 (1 - 2 / 2)